Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

GSK is officially cutting ties with Ideaya Biosciences, handing back two clinical programs as part of the termination of a ...

If you are wondering whether GSK is still good value after its strong run, you are not alone. This article will walk through ...

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...

Thursday, the FDA addressed the shortfall with a label expansion for GSK’s Blujepa, which brings an oral option and a new ...

Coming up in the back half of December, the FDA will issue a verdict on Vanda Pharmaceuticals’ gastroparesis drug tradipitant ...

The drug is from a new class of antibiotics, the first new class in decades to be approved as a treatment for gonorrhea, ...

We recently published 13 Best ADR Stocks to Invest In. GSK plc (NYSE:GSK) is one of the best ADR stocks. GSK plc (NYSE:GSK) ...

GSK and Ideaya first linked up in 2020 to advance novel therapies for solid tumors. It is unclear why the pharma terminated ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps.